Quantcast
Connect with us

Regeneron says early trials promising for COVID-19 treatment

Published

on

A 3D print of a spike protein of SARS-CoV-2, the virus that causes COVID-19, in front of a 3D print of a SARS-CoV-2 virus particle Handout National Institutes of Health/AFP/File

The US biotech firm Regeneron said Tuesday its antibody cocktail against the coronavirus reduced viral load and recovery time in non-hospitalized Covid-19 patients during an early-stage clinical trial.

“We are highly encouraged by the robust and consistent nature of these initial data,” said George Yancopoulos, the company’s president and chief scientific officer.

ADVERTISEMENT

“We have begun discussing our findings with regulatory authorities while continuing our ongoing trial,” he added.

“We have begun discussing our findings with regulatory authorities while continuing our ongoing trial,” he added.

The results related to the first 275 patients recruited into Regeneron’s Phase 1 trial. The patients were randomized to receive either a low-dose, high-dose or placebo of the drug, and they were also classed by whether their bodies had mounted their own antibody response or not.

The greatest treatment benefit was seen in patients who had not mounted their own effective immune response, which suggested the drug, called REGN-COV2, could act as a substitute in the absence of naturally occurring antibodies, according to Yancopoulos.

Regeneron said it would recruit 1,300 patients for the next stages of the outpatient trial. It is also concurrently running late-stage trials for hospitalized Covid-19 patients and for the drug’s potential use as a prophylaxis.

ADVERTISEMENT

Antibodies are infection-fighting proteins made by the immune system that can bind to particular structures on the surfaces of pathogens and prevent them from invading cells.

Vaccines work by teaching the body to make its own antibodies, while scientists are also testing ready-made antibodies from the blood of recovered patients, called convalescent plasma.

But it is not possible to make convalescent plasma a mass treatment.

ADVERTISEMENT

Researchers can also comb through the antibodies produced by recovered patients and select the most effective out of thousands, and then manufacture it at scale.

Regeneron uses a multi-antibody strategy to decrease the chances that the virus will mutate in order to evade the blocking action of a single antibody, an approach the company detailed in a recent study in Science.

ADVERTISEMENT

Last year, a triple-antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus.

Also on Tuesday, the biotech firm Moderna — one of the frontrunners in the race to develop a Covid-19 vaccine — reported results from the Phase 1 portion of its clinical trial that showed its drug was safe and generated a strong immune response among a group of 40 older adults.

Moderna’s Phase 3 trial, the final phase before possible approval, is also underway and could report interim results by the end of the year.

ADVERTISEMENT


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

2020 Election

Trump tries to shame media out of covering the pandemic with frantic all-caps tweet

Published

on

With one week to go until the 2020 presidential election, President Donald Trump does not want to talk about the novel coronavirus pandemic.

In a frantic all-caps tweet posted Tuesday morning, the president once again ranted about all the attention the media is giving to a pandemic that has killed more than 220,000 Americans in just eight months.

"ALL THE FAKE NEWS MEDIA WANTS TO TALK ABOUT IS COVID, COVID, COVID," the president wrote. "ON NOVEMBER 4th, YOU WON’T BE HEARING SO MUCH ABOUT IT ANYMORE. WE ARE ROUNDING THE TURN!!!"

Despite the president's claims, there is no indication that America is "rounding the corner" on the pandemic.

Continue Reading

COVID-19

Cars, electro and sequins: drive-in raves in virus-hit US

Published

on

Clearly visible from afar with her flashing earrings and sequined jacket, Charity Valente is attending her first drive-in rave: a night of electronic music where the party-goers are in or around their cars, owing to the coronavirus pandemic.

"We've been waiting for live music for seven months," she said, after driving four hours from Pittsburgh to see US jam group "Disco Biscuits."

On a remote hilltop in Scranton, Pennsylvania, dubbed "Electric City" because it was home to the first electric streetcars in America, more than 100 cars are lined up, their headlights trained on the stage where two giant screens have been set up.

Continue Reading
 

Breaking Banner

‘He doesn’t care’: Kentucky residents bury McConnell for jamming through Barrett while millions suffer

Published

on

Senate Majority Leader Mitch McConnell (R-KY) on Monday night crowed about jamming through Amy Coney Barrett's nomination to the Supreme Court -- and then promptly adjourned the Senate until after the election.

The decision to adjourn was particularly striking because it meant that no economic relief would pass the Senate before election day during a time when millions of people are unemployed and under the threat of being evicted from their homes.

Continue Reading
 
 
Democracy is in peril. Invest in progressive news. Join Raw Story Investigates for $1. Go ad-free. LEARN MORE